Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation.
Two different isoforms of cyclooxygenases, COX-1 and COX-2, are constitutively expressed under normal physiological conditions of the central nervous system, and accumulating data indicate that both isoforms may be involved in different pathological conditions. However, the distinct role of COX-1 and COX-2 and the probable interaction between them in neuroinflammatory conditions associated with Alzheimer's disease are conflicting issues. The aim of this study was to elucidate the comparable role of each COX isoform in neuroinflammatory response induced by β-amyloid peptide (Aβ). Using histological and biochemical methods, 13 days after stereotaxic injection of Aβ into the rat prefrontal cortex, hippocampal neuroinflammation and neuronal injury were confirmed by increased expression of tumor necrosis factor-alpha (TNF-α) and COX-2, elevated levels of prostaglandin E2 (PGE2), astrogliosis, activation of caspase-3, and neuronal cell loss. Selective COX-1 or COX-2 inhibitors, SC560 and NS398, respectively, were chronically used to explore the role of COX-1 and COX-2. Treatment with either COX-1 or COX-2 selective inhibitor or their combination equally decreased the level of TNF-α, PGE2, and cleaved caspase-3 and attenuated astrogliosis and neuronal cell loss. Interestingly, treatment with COX-1 selective inhibitor or the combined COX inhibitors prevented the induction of COX-2. These results indicate that the activity of both isoforms is detrimental in neuroinflammatory conditions associated with Aβ, but COX-1 activity is necessary for COX-2 induction and COX-2 activity seems to be the main source of PGE2 increment.
Dargahi
Leila
L
Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nasiraei-Moghadam
Shiva
S
Abdi
Azadeh
A
Khalaj
Leila
L
Moradi
Fatemeh
F
Ahmadiani
Abolhassan
A
D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D000818:Animals; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D004660:Encephalitis / Q000139:chemically induced* / Q000201:enzymology* / Q000473:pathology; D004790:Enzyme Induction / Q000187:drug effects*; D006624:Hippocampus / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D007527:Isoenzymes / Q000378:metabolism*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016229:Amyloid beta-Peptides; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D014409:Tumor Necrosis Factor-alpha; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015232:Dinoprostone